Insilico Medicine (03696) Nominates New-Generation Small-Molecule GIPR Antagonist with Potential for Obesity and Related Disease Intervention

Stock News12:26

Insilico Medicine (03696) announced that, driven by its proprietary generative AI platform, the company has nominated ISM1354, a potential best-in-class, new-generation small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, as a preclinical candidate compound (PCC), with potential for intervention in obesity, type 2 diabetes, and related diseases, and with the prospect of expanding into the cardiovascular disease field.

In January of this year, the company announced the nomination of another GIPR antagonist, ISM0676, which achieved up to 31.3% weight loss when combined with semaglutide in a humanized mouse model.

By comparison, the newly nominated PCC not only maintains favorable drug-like properties but also achieves multidimensional optimization in pharmacokinetics (PK), safety profile, and other aspects.

To date, Insilico Medicine has announced the nomination of 10 PCCs within the first nine months of 2026, setting a new company record for annual pipeline output and pushing the total number of PCCs nominated since 2021 to 34, thereby validating generative AI R&D efficiency through reproducible real-world cases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196592931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 12:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196592931","market":"hk","top_or_hot":-1,"title":"Insilico Medicine (03696) Nominates New-Generation Small-Molecule GIPR Antagonist with Potential for Obesity and Related Disease Intervention","media":"Stock News","content":"<p><b>Insilico Medicine</b> (<b>03696</b>) announced that, driven by its proprietary generative AI platform, the company has nominated ISM1354, a potential best-in-class, new-generation small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, as a preclinical candidate compound (PCC), with potential for intervention in obesity, type 2 diabetes, and related diseases, and with the prospect of expanding into the cardiovascular disease field.<br><br>In January of this year, the company announced the nomination of another GIPR antagonist, ISM0676, which achieved up to 31.3% weight loss when combined with semaglutide in a humanized mouse model.<br><br>By comparison, the newly nominated PCC not only maintains favorable drug-like properties but also achieves multidimensional optimization in pharmacokinetics (PK), safety profile, and other aspects.<br><br>To date, <b>Insilico Medicine</b> has announced the nomination of 10 PCCs within the first nine months of 2026, setting a new company record for annual pipeline output and pushing the total number of PCCs nominated since 2021 to 34, thereby validating generative AI R&D efficiency through reproducible real-world cases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine (03696) Nominates New-Generation Small-Molecule GIPR Antagonist with Potential for Obesity and Related Disease Intervention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine (03696) Nominates New-Generation Small-Molecule GIPR Antagonist with Potential for Obesity and Related Disease Intervention\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-30 12:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Insilico Medicine</b> (<b>03696</b>) announced that, driven by its proprietary generative AI platform, the company has nominated ISM1354, a potential best-in-class, new-generation small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, as a preclinical candidate compound (PCC), with potential for intervention in obesity, type 2 diabetes, and related diseases, and with the prospect of expanding into the cardiovascular disease field.<br><br>In January of this year, the company announced the nomination of another GIPR antagonist, ISM0676, which achieved up to 31.3% weight loss when combined with semaglutide in a humanized mouse model.<br><br>By comparison, the newly nominated PCC not only maintains favorable drug-like properties but also achieves multidimensional optimization in pharmacokinetics (PK), safety profile, and other aspects.<br><br>To date, <b>Insilico Medicine</b> has announced the nomination of 10 PCCs within the first nine months of 2026, setting a new company record for annual pipeline output and pushing the total number of PCCs nominated since 2021 to 34, thereby validating generative AI R&D efficiency through reproducible real-world cases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1196592931","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196592931","pubTimestamp":1790742390,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Insilico Medicine (03696) announced that, driven by its proprietary generative AI platform, the company has nominated ISM1354, a potential best-in-class, new-generation small-molecule...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能","GIPR":"Generation Income Properties Inc.","BK4160":"多样化房地产投资信托v","BK1141":"生命科学工具和服务"},"translate_title":"Insilico Medicine(03696)提名新一代小分子GIPR拮抗剂，具肥胖及相关疾病干预潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GIPR":1,"03696":1},"content_text":"Insilico Medicine (03696) announced that, driven by its proprietary generative AI platform, the company has nominated ISM1354, a potential best-in-class, new-generation small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, as a preclinical candidate compound (PCC), with potential for intervention in obesity, type 2 diabetes, and related diseases, and with the prospect of expanding into the cardiovascular disease field.In January of this year, the company announced the nomination of another GIPR antagonist, ISM0676, which achieved up to 31.3% weight loss when combined with semaglutide in a humanized mouse model.By comparison, the newly nominated PCC not only maintains favorable drug-like properties but also achieves multidimensional optimization in pharmacokinetics (PK), safety profile, and other aspects.To date, Insilico Medicine has announced the nomination of 10 PCCs within the first nine months of 2026, setting a new company record for annual pipeline output and pushing the total number of PCCs nominated since 2021 to 34, thereby validating generative AI R&D efficiency through reproducible real-world cases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196592931","isCrawlerRequest":true}